(XNCR) Xencor - Overview
Stock: Monoclonal Antibodies, Bispecific Antibodies, T-Cell Engagers, XmAb Fc Technologies
| Risk 5d forecast | |
|---|---|
| Volatility | 60.2% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.16 |
| Alpha | -47.47 |
| Character TTM | |
|---|---|
| Beta | 1.423 |
| Beta Downside | 1.893 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.87% |
| CAGR/Max DD | -0.38 |
EPS (Earnings per Share)
Revenue
Description: XNCR Xencor February 23, 2026
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharma headquartered in Pasadena, California, that engineers monoclonal and bispecific antibodies for asthma, autoimmune disorders, oncology and infectious diseases. Its marketed portfolio includes Ultomiris for rare renal and neuromuscular conditions, Monjuvi for relapsed/refractory diffuse large B-cell lymphoma, and the COVID-19 antibody Sotrovimab, while its pipeline spans more than a dozen candidates such as XmAb819 (RCC), XmAb541 (ovarian cancer) and Vudalimab (mCRPC).
Recent data show Xencor’s lead bispecific XmAb819 achieved a 30% objective response rate in a Phase II renal cell carcinoma trial, and Vudalimab advanced to a positive Phase II read-out in metastatic castration-resistant prostate cancer. The company also secured a new collaboration with Roche to co-develop XmAb Fc-engineered platforms, adding $150 million in upfront payments to its balance sheet.
Financially, Xencor reported Q4 2025 revenue of $140 million, a net loss of $200 million, and ended the quarter with $820 million in cash and market-able securities, supporting its R&D spend of $120 million. The broader biotechnology sector is benefiting from accelerated FDA pathways and strong investor appetite for bispecific antibody technologies, with the S&P Biotech Index up roughly 8% year-to-date.
For a deeper dive, consider reviewing ValueRay’s analyst resources for additional context.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -138.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -2.48 > 1.0 |
| NWC/Revenue: 258.1% < 20% (prev 473.2%; Δ -215.1% < -1%) |
| CFO/TA -0.16 > 3% & CFO -139.0m > Net Income -138.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.4m) vs 12m ago 16.23% < -2% |
| Gross Margin: 64.74% > 18% (prev 0.88%; Δ 6387 % > 0.5%) |
| Asset Turnover: 18.07% > 50% (prev 10.34%; Δ 7.73% > 0%) |
| Interest Coverage Ratio: -1.36 > 6 (EBITDA TTM -68.6m / Interest Expense TTM 58.5m) |
Altman Z'' -3.67
| A: 0.50 (Total Current Assets 518.4m - Total Current Liabilities 86.5m) / Total Assets 868.8m |
| B: -0.91 (Retained Earnings -789.3m / Total Assets 868.8m) |
| C: -0.09 (EBIT TTM -79.5m / Avg Total Assets 926.2m) |
| D: -3.23 (Book Value of Equity -787.4m / Total Liabilities 243.5m) |
| Altman-Z'' Score: -3.67 = D |
Beneish M -2.03
| DSRI: 1.30 (Receivables 21.8m/10.2m, Revenue 167.4m/101.7m) |
| GMI: 1.36 (GM 64.74% / 87.87%) |
| AQI: 0.94 (AQ_t 0.30 / AQ_t-1 0.31) |
| SGI: 1.65 (Revenue 167.4m / 101.7m) |
| TATA: 0.00 (NI -138.7m - CFO -139.0m) / TA 868.8m) |
| Beneish M-Score: -2.03 (Cap -4..+1) = BB |
What is the price of XNCR shares?
Over the past week, the price has changed by -1.13%, over one month by -12.97%, over three months by -31.84% and over the past year by -24.24%.
Is XNCR a buy, sell or hold?
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the XNCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.8 | 152.7% |
| Analysts Target Price | 28.8 | 152.7% |
XNCR Fundamental Data Overview February 20, 2026
P/B = 1.3179
Revenue TTM = 167.4m USD
EBIT TTM = -79.5m USD
EBITDA TTM = -68.6m USD
Long Term Debt = 115.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 49.3m USD (from shortTermDebt, last quarter)
Debt = 202.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 174.1m USD (from netDebt column, last quarter)
Enterprise Value = 541.2m USD (809.8m + Debt 202.4m - CCE 471.0m)
Interest Coverage Ratio = -1.36 (Ebit TTM -79.5m / Interest Expense TTM 58.5m)
EV/FCF = -3.77x (Enterprise Value 541.2m / FCF TTM -143.7m)
FCF Yield = -26.55% (FCF TTM -143.7m / Enterprise Value 541.2m)
FCF Margin = -85.85% (FCF TTM -143.7m / Revenue TTM 167.4m)
Net Margin = -82.91% (Net Income TTM -138.7m / Revenue TTM 167.4m)
Gross Margin = 64.74% ((Revenue TTM 167.4m - Cost of Revenue TTM 59.0m) / Revenue TTM)
Gross Margin QoQ = 87.62% (prev 93.92%)
Tobins Q-Ratio = 0.62 (Enterprise Value 541.2m / Total Assets 868.8m)
Interest Expense / Debt = 3.79% (Interest Expense 7.67m / Debt 202.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -62.8m (EBIT -79.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.99 (Total Current Assets 518.4m / Total Current Liabilities 86.5m)
Debt / Equity = 0.32 (Debt 202.4m / totalStockholderEquity, last quarter 625.3m)
Debt / EBITDA = -2.54 (negative EBITDA) (Net Debt 174.1m / EBITDA -68.6m)
Debt / FCF = -1.21 (negative FCF - burning cash) (Net Debt 174.1m / FCF TTM -143.7m)
Total Stockholder Equity = 640.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.98% (Net Income -138.7m / Total Assets 868.8m)
RoE = -21.65% (Net Income TTM -138.7m / Total Stockholder Equity 640.8m)
RoCE = -10.52% (EBIT -79.5m / Capital Employed (Equity 640.8m + L.T.Debt 115.2m))
RoIC = -9.21% (negative operating profit) (NOPAT -62.8m / Invested Capital 681.7m)
WACC = 9.58% (E(809.8m)/V(1.01b) * Re(11.23%) + D(202.4m)/V(1.01b) * Rd(3.79%) * (1-Tc(0.21)))
Discount Rate = 11.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.59%
Fair Price DCF = unknown (Cash Flow -143.7m)
EPS Correlation: -7.23 | EPS CAGR: -7.45% | SUE: 1.88 | # QB: 3
Revenue Correlation: -34.31 | Revenue CAGR: -41.22% | SUE: -0.33 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.63 | Chg30d=-0.004 | Revisions Net=+0 | Analysts=8
EPS next Year (2026-12-31): EPS=-2.62 | Chg30d=+0.047 | Revisions Net=+3 | Growth EPS=-43.5% | Growth Revenue=-3.4%